#Canada #Hamilton #AtomVie #Ariceum #SANTANA-225

AtomVie Global Radiopharma Supplies the First Patient Dose of 225Ac-SSO110 for SANTANA-225 Clinical Trial

On November 12, 2025, AtomVie Global Radiopharma announced a significant achievement in the realm of oncology with the successful supply of the initial patient dose of 225Ac-SSO110 to Ariceum Therapeutics. This milestone is critical as it kicks off the Phase 1/2 SANTANA-225 clinical trial, aimed at addressing extensive-stage small cell lung cancer (SCLC) and Merkel cell carcinoma (MCC).

A Groundbreaking Collaboration

AtomVie, recognized as a leading radiopharmaceutical Contract Development and Manufacturing Organization (CDMO), joined forces with Ariceum for this endeavor. The importance of 225Ac-SSO110, a potential first-in-class treatment targeting the somatostatin type 2 receptor (SSTR2), cannot be overstated in the ongoing fight against aggressive cancers. Both companies share a commitment to delivering high-quality solutions in oncology, and this collaboration exemplifies that mission.

Bruno Paquin, CEO of AtomVie, expressed pride in the partnership, stating, “We are honored to partner with Ariceum to deliver the critical supply of 225Ac-SSO110. Our mission of transforming patients' lives with high-quality radiopharmaceuticals drives every step of our work.” This sentiment reflects the core values that guide AtomVie’s operations.

The Significance of SANTANA-225

The SANTANA-225 clinical trial is a pivotal study that evaluates the efficacy of 225Ac-SSO110 in patients with extensive-stage SCLC and MCC, both of which have limited treatment options and poor prognoses. Manuel Sturzbecher-Höhne, Ariceum's Chief Technology Officer, remarked, “Dosing the first patient in our SANTANA-225 clinical trial marks a significant milestone for Ariceum. We are proud to partner with AtomVie on the manufacturing of 225Ac-SSO110.” This partnership is built upon a shared commitment to ensuring robust and reliable production of this promising therapy.

Leveraging State-of-the-Art Facilities

The collaboration between AtomVie and Ariceum leverages AtomVie’s state-of-the-art cGMP facilities and technical expertise to ensure that 225Ac-SSO110 is manufactured with consistency and uncompromising quality. Such endeavors are critical in maintaining a reliable supply chain for clinical trials, especially in oncology, where time is of the essence in patient treatment.

AtomVie is also constructing a new, purpose-built facility that spans 72,300 square feet. This facility, set to launch at the end of 2025, represents a significant investment in the future of radiopharmaceutical manufacturing and is expected to enhance AtomVie’s capabilities in serving a growing client roster across a spectrum of clinical studies.

A Bright Future in Oncology

As AtomVie advances the production of 225Ac-SSO110, the implications of this partnership extend beyond regulatory achievements. AtomVie and Ariceum's dedication to developing transformative therapies charts a positive and hopeful course for patients battling aggressive cancers. The next phases of clinical development will be closely observed by stakeholders in the medical and investment fields.

For further information about AtomVie Global Radiopharma and their innovative solutions, you can visit AtomVie’s official website. Similarly, Ariceum Therapeutics is broadening its impact within the oncology landscape with additional innovative candidates like ATT001, showcasing the company's ambition in delivering cutting-edge treatments.

In conclusion, this partnership not only heralds a new era in clinical therapies for difficult cancers but also showcases the potential of collaboration in pushing the boundaries of what is possible in modern medicine.